• Return to Headlines

Shares of Progenics Pharmaceuticals Rank the Lowest in Terms of Free Cash Flow Per Share in the Biotechnology Industry (PGNX, RGEN, AMAG, LGND, MDVN)

By James Quinn

Below are the three companies in the Biotechnology industry with the lowest (positive) free cash flow per share. FCF/share is a valuable metric signaling a company's ability to facilitate growth in the business.

Progenics Pharmaceuticals ranks lowest with a FCF per share of $0.19. Repligen is next with a FCF per share of $0.39. AMAG Pharmaceuticals ranks third lowest with a FCF per share of $0.50.

Ligand Pharmaceuticals follows with a FCF per share of $1.01, and Medivation rounds out the bottom five with a FCF per share of $1.50.

SmarTrend recommended that subscribers consider buying shares of Medivation on July 7th, 2016 as our technology indicated a new Uptrend was in progress when shares hit $62.61. Since that recommendation, shares of Medivation have risen 30.1%. We continue to monitor Medivation for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: lowest free cash flow per share progenics pharmaceuticals repligen amag pharmaceuticals ligand pharmaceuticals Medivation